Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial

NCT04972721 · View on ClinicalTrials.gov ↗

Study Summary

Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial including the trial medicine participants have been taking. When the SELECT trial ends, participants will no longer get the medicine participants got in the study, even if participants decide to take part in the SELECT-LIFE study. Participants will not get any specific treatment or medicine as part of the SELECT-LIFE study, and participants will be treated as participants normally would by their own doctor. The SELECT-LIFE study will last for up to 10 years after SELECT trial ends, and participants will be asked to fill in a questionnaire about their health every 6 months.

Conditions Studied

Interventions

  • OTHER No treatment given

Study Locations (20)

São Paulo

  • Instituto de Pesquisa Clínica de Campinas — Campinas
  • CIP Centro Integrado de Pesquisas do Hospital de Base — São José do Rio Preto
  • CPQuali Pesquisa Clínica Ltda — São Paulo
  • CPCLIN - Centro de Pesquisas Clínicas — São Paulo
  • Instituto Dante Pazzanese de Cardiologia — São Paulo
  • Departamento de Gastroenterologia - HCFMUSP — São Paulo
  • Instituto do Coração - HCFMUSP — São Paulo
  • Master Centre for Brazil — Säo Paulo

Other

  • Master Centre for Algeria — Algiers
  • Master Centre for Argentina — Prov. de Buenos Aires
  • Instituto Brasil de Pesquisa Clinica — Rio de Janeiro

New Jersey

  • Master Centre for USA — Plainsboro

New South Wales

  • Master Centre for Australia — North Sydney

Estado de Bahia

  • Cárdio Pulmonar da Bahia — Salvador

Federal District

  • Hospital do Coração do Brasil — Brasília

Minas Gerais

  • Eurolatino Medical Research Center — Uberlândia

Paraná

  • Núcleo de Pesquisa Clínica S/S — Curitiba

Trial Details

FieldValue
Enrollment Target 3,439 participants
Start Date 2023-09-01
Est. Completion 2025-08-25

Sponsor

Novo Nordisk A/S

189 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04972721

The ClinicalTrials.gov registry entry for NCT04972721 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,439 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 189 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention — of which No treatment given is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04972721 reports 20 study locations spanning 11 distinct geographic areas — top geographies include São Paulo, Other, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04972721 about?

NCT04972721 is a clinical study titled "SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial". Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial incl...

What is the current status of trial NCT04972721?

This trial is currently completed. The enrollment target is 3,439 participants. The study started on 2023-09-01. Estimated completion is 2025-08-25.

What conditions does trial NCT04972721 study?

This clinical trial studies the following conditions: Obesity, Overweight. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04972721?

The interventions under investigation include: No treatment given (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04972721?

This trial is sponsored by Novo Nordisk A/S, which has 189 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04972721 being conducted?

This trial has 20 study locations across New Jersey, New South Wales, Estado de Bahia, Federal District, Minas Gerais. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial